Upon joining the study, eligibility is confirmed based on specific criteria such as age, diagnosis of Crohn’s disease, and previous treatment history.

Written informed consent is required, and the ability to comply with the study schedule is assessed.

The induction phase involves taking etrasimod arginine tablets orally. The dosage and frequency are determined by the study protocol.

This phase aims to evaluate the initial response to the medication over a specified period, typically up to 14 weeks.

During the induction phase, the response to treatment is assessed through clinical evaluations and endoscopic examinations.

The primary goal is to observe any endoscopic response and clinical remission, which are key indicators of the medication’s effectiveness.

If the induction therapy is successful, the patient may continue to the maintenance phase, which involves ongoing administration of etrasimod arginine tablets.

This phase is designed to maintain the therapeutic benefits achieved during induction and is evaluated over a longer period, potentially up to 52 weeks.

Throughout the trial, regular monitoring is conducted to ensure safety and track the progress of the treatment.

This includes periodic clinical assessments, laboratory tests, and endoscopic evaluations to monitor the disease activity and any side effects.

Upon completion of the trial, a final assessment is conducted to evaluate the overall effectiveness and safety of the treatment.

The results contribute to the understanding of etrasimod arginine as a potential therapy for Crohn’s disease.